Mod GRF 1-29 — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Mod GRF 1-29

Also known as: CJC-1295 without DAC, CJC-1295 no DAC, CJC1295 no DAC, Modified GRF 1-29, ModGRF1-29, Mod-GRF 1-29, Mod GRF (1-29), tetrasubstituted GRF(1-29)

Growth Hormone-Releasing Hormone (GHRH) Analogue / Growth Hormone Secretagogue

Not FDA-approvedLast updated: October 31, 2026Based on 7 peer-reviewed studies

What it is

Mod GRF 1-29, also called CJC-1295 without DAC, is a peptide people use to trigger short bursts of their own growth hormone, usually alongside a GHRP such as ipamorelin. It is a modified, more stable version of the natural hormone signal (GHRH 1-29) and lasts about 30 minutes in the body, so it is injected one to three times a day rather than weekly. Not FDA-approved; banned by WADA.

The scientific side

Mod GRF 1-29 (CJC-1295 without DAC) is a synthetic analogue of human growth hormone-releasing hormone (GHRH 1-29) with four amino-acid substitutions (D-Ala2, Gln8, Ala15, Leu27) that make it resistant to dipeptidylpeptidase-IV cleavage and more stable than native GHRH(1-29) (sermorelin). It acts as a GHRH receptor agonist on anterior pituitary somatotrophs, producing a pulse of GH release and downstream IGF-1. Unlike CJC-1295 with DAC, it carries no Drug Affinity Complex, so it does not bind serum albumin: its half-life is roughly 30 minutes rather than days, and GH release stays pulsatile. The half-life and dosing data in the published CJC-1295 trials describe the DAC form and do not apply to Mod GRF 1-29. It is commonly paired with a GHRP (ghrelin-receptor agonist such as ipamorelin, GHRP-2 or GHRP-6), which acts on a separate receptor and amplifies the GH pulse.

Class: Growth Hormone-Releasing Hormone (GHRH) Analogue / Growth Hormone Secretagogue

Not FDA-approvedLow researchHormonesShort-acting GHRH analog (tetrasubstituted)

At a glance

What it isGRF(1-29), the active piece of growth hormone-releasing hormone, with four amino acids swapped to resist breakdown. Often sold as "CJC-1295 without DAC".
FDA statusNot approved for any use. Not named on FDA's compounding safety-risk page; an FDA advisory committee voted against the non-DAC forms of CJC-1295 in 2024.
Used forShort growth hormone pulses, usually injected daily before bed and often paired with a GHRP.
Human evidenceNone published for Mod GRF 1-29 itself.
Half-lifeNot published. It is expected to be short, like sermorelin, but this has not been measured.
Banned in sportYes, as a GHRH analogue under WADA S2.2.4, prohibited at all times.

What is Mod GRF 1-29?

Mod GRF 1-29 ("modified GRF 1-29") is the first 29 amino acids of growth hormone-releasing hormone, the same sequence as Sermorelin, with four amino acids substituted. The changes are usually listed as D-Ala2, Gln8, Ala15 and Leu27. Researchers describe this backbone as "tetrasubstituted" GRF(1-29).

It is the core of CJC-1295 without the albumin-binding DAC group, which is why vendors also call it "CJC-1295 without DAC" or "CJC-1295 no DAC". Check labels carefully: the two products are dosed and behave very differently.

Sources: [1] [2]

How does it work?

Like sermorelin, it binds GHRH receptors on the pituitary to trigger a pulse of the body's own growth hormone.

The substitutions target the reason native GRF is so short-lived: an enzyme in plasma, DPP-IV, inactivates GRF by cutting the bond after position 2. Analog work in the 1990s showed that changing position 2 (and position 15) made GRF far more stable in plasma and more active in animals. How long Mod GRF 1-29 itself lasts in people has not been published.

Pharmacokinetics

Half-lifeNot published for Mod GRF 1-29
MetabolismDesigned to resist DPP-IV, the plasma enzyme that inactivates native GRF
ClearanceNot characterized
RouteSold for injection under the skin; no human route studies

Sources: [3] [1]

Is it FDA-approved?

No. It has never been approved for any use, and no company has run trials of it.

FDA's page of compounding substances with significant safety risks does not name Mod GRF 1-29. In December 2024, FDA's Pharmacy Compounding Advisory Committee voted against the non-DAC forms of CJC-1295 for the 503A bulks list (0-13 for the free base, 1-12 for the acetate), along with the DAC forms.

  • WADA: S2.2.4 Growth hormone releasing factors (covered as a GHRH analogue; prohibited at all times)

Sources: [4] [5]

History

Its history runs through two other peptides. Sermorelin (GRF 1-29) was an approved drug from 1990 to 2008, but native GRF breaks down within minutes. In the early 1990s, researchers made substituted GRF(1-29) analogs that resisted plasma enzymes.

ConjuChem used a tetrasubstituted GRF(1-29) as the base for CJC-1295, adding the DAC group to bind albumin. The backbone without DAC was never developed as a drug; it reached the market through research-peptide vendors, which is where the "Mod GRF 1-29" and "CJC-1295 no DAC" names come from.

Sources: [3] [1]

Regulatory timeline

  1. December 4, 2024FDA's Pharmacy Compounding Advisory Committee votes against the non-DAC forms of CJC-1295 for the 503A bulks list (0-13 free base, 1-12 acetate). Source
  2. As of April 2026FDA's compounding safety-risk page does not name Mod GRF 1-29. Source

Side effects

There are no published human side-effect data for Mod GRF 1-29. Side effects reported for related GHRH analogs include injection-site reactions and facial flushing (sermorelin), and raised blood sugar and fluid retention (tesamorelin), but those are different drugs.

Because it raises growth hormone, the same cautions apply as for other GHRH analogs: people with active cancer or pituitary disease should not use it without medical advice.

Who should not use it

  • No established contraindications: Mod GRF 1-29 has never been studied in humans.
  • Competitive athletes: Prohibited at all times under WADA S2.2.4 (growth hormone releasing factors), per the 2026 World Anti-Doping Code Prohibited List. Verified against the current WADA list as of October 2026.
  • Active cancer or pituitary disease: it raises growth hormone and IGF-1.
  • Pregnancy and breastfeeding: not studied.

No published human data for Mod GRF 1-29.

Sources: [6] [7]

What does the research show?

No clinical trial or published human study has tested Mod GRF 1-29. A 2026 review of performance-enhancing GH peptides describes the gap between this kind of self-administration and the clinical evidence.

The closest evidence is indirect: sermorelin raised growth hormone and, at twice-daily doses, IGF-1 in older adults; and CJC-1295 with DAC, which shares its backbone, raised growth hormone and IGF-1 in healthy adults. Neither tells you the effect, dose or half-life of Mod GRF 1-29.

Studied for

  • No human studies published
  • Related analogs: GRF(1-29) stability in plasma and GH release in animals (1990s)

Sources: [8] [9] [10]

FAQ

Is Mod GRF 1-29 the same as CJC-1295?

Not quite. It is the same backbone without the DAC group. CJC-1295 with DAC binds albumin and lasts about a week; Mod GRF 1-29 does not.

Sources: [1]

Has Mod GRF 1-29 been tested in humans?

No published human study exists. Claims about its effects are extrapolated from sermorelin and CJC-1295.

Sources: [8]

What is its half-life?

It has not been published. It is often quoted as about 30 minutes online, but no peer-reviewed study has measured it.

Is Mod GRF 1-29 FDA-approved?

No. FDA's advisory committee voted against the non-DAC forms of CJC-1295 for compounding in December 2024.

Sources: [5]

Why is it paired with Ipamorelin?

They act on different receptors: Mod GRF 1-29 on the GHRH receptor and Ipamorelin on the ghrelin receptor. No published trial has tested the combination.

Sources: [11]

Is Mod GRF 1-29 banned in sport?

Yes. WADA S2.2.4 covers growth hormone-releasing hormone and its analogues, prohibited at all times.

Sources: [12]

Citations

  1. Jetté L, et al. hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005. PMID 15817669
  2. Memdouh S, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal 2021. PMID 34665524
  3. Kubiak TM, et al. Position 2 and position 2/Ala15-substituted analogs of bovine GRF with enhanced metabolic stability and improved in vivo bioactivity. J Med Chem 1993. PMID 8464043
  4. FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  5. FDA: final summary minutes of the Pharmacy Compounding Advisory Committee meeting, December 4, 2024. fda.gov/media/185642/download
  6. Prakash A, Goa KL. Sermorelin: a review of its use in children with idiopathic growth hormone deficiency. BioDrugs 1999. PMID 18031173
  7. EGRIFTA SV (tesamorelin) for injection, prescribing information, DailyMed (current label). dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
  8. Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis. Front Endocrinol 2026. PMID 42395176
  9. Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab 2006. PMID 16352683
  10. Corpas E, et al. GHRH-(1-29) twice daily reverses the decreased GH and IGF-I levels in old men. J Clin Endocrinol Metab 1992. PMID 1379256
  11. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. PMID 9849822
  12. World Anti-Doping Agency: Prohibited List 2026 (copy hosted by SEGAS). segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf

Sources

Administration & storage

Administration
Subcutaneous injection (community reports)
Storage
No reviewed study describes storage conditions for Mod GRF 1-29.
Cautions
CJC-1295 is not approved by any regulatory authority for performance enhancement or general clinical use; human safety data beyond short-term pharmacokinetic studies are lacking.,Potential adverse effects associated with GH-axis modulation (including prolactin/cortisol elevations, appetite changes, dysglycaemia, fluid retention, myalgia/arthralgia, and injection-site reactions) have been reported in the context of GH-axis peptides in this class; specific long-term safety data for CJC-1295 are not available from the reviewed literature.,Products sold outside regulated channels may be mislabelled or contaminated; an illicitly manufactured pharmaceutical preparation containing CJC-1295 was identified by Norwegian police and customs authorities in 2009.,CJC-1295 is classified as a prohibited substance by WADA; use by competitive athletes carries significant anti-doping consequences.,Sterile technique is essential for any injectable compound to minimise infection risk.

Legal & regulatory status

US FDA

Not approved by the FDA for any indication. Classified as a prohibited performance-enhancing substance by WADA. (PMID: 41966639, 41880199, 31849 — see WADA status below)

WADA

Prohibited by the World Anti-Doping Agency (WADA) under Section S2 of the Prohibited List as a growth hormone-releasing hormone analogue.

Health Canada

Not stated in reviewed literature — requires manual verification